SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (220)9/20/1997 10:56:00 PM
From: JOSEPH VON MEISTER   of 1826
 
MGI Pharma is the source. Company has Orphan drug on head and neck through 2001. I am told they will get orphan drug protection on the second indication for Salagen, when/if they get it.

Head and Neck indication orphan drug protection expires 4/01. MGI has an agreement with E-Merk of Germany to provide it with pilocarpine supplies for systemic use exclusively. E-Merk supplies roughly 95% of the world's pilocarpine.

JVM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News